Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplant for Hematological Malignancy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Donor will be \<75 years of age and in good health.~* Recipients will be \< or = 55 years, will have normal organ function (excluding bone marrow) and will have a Karnofsky activity assessment \> or = 90%.~* Recipients with related or unrelated donor matched at the HLA A, B, DRB1 loci, or mismatched related or unrelated (if \< 35 years old) at a single HLA A, B, DRB1 locus.~* Recipients will be eligible in one of the following disease categories~* Chronic myelogenous leukemia in accelerated phase or in post blast crisis second or greater chronic phase; or in chronic phase but intolerant of or resistant to tyrosine kinase inhibitors.~* Acute myelocytic leukemia in first or greater remission, or first, second or third relapse.~* Acute lymphocytic leukemia in the 2nd or greater bone marrow remission.~* High risk children will be transplanted in first remission if they meet criteria~* Myelodysplastic syndrome.~* Myeloproliferative Diseases - (i.e. myelofibrosis, chronic myelomonocytic leukemia (CMML))~* Juvenile myelomonocytic leukemia~* Chronic lymphocytic leukemia~* Advanced non-Hodgkin's (NHL).~* Advanced Hodgkin's disease beyond PR2 (\> CR3, \> PR3).~* Multiple Myeloma after initial therapy.~* Donors and recipients signed informed consent~Exclusion Criteria~donors and recipients should meet the following test criteria.~* required for donors:~  * anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-priming.~ * CBC, platelet count each day of apheresis, day 0 (or 1 or 2 as needed)~* required for recipients:~  * anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-transplant.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- PBSC: No TBI (Type: EXPERIMENTAL): Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Peripheral Blood Stem Cells (PBSC) as a source of transplant
- Marrow : No TBI (Type: EXPERIMENTAL): Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Bone Marrow as a source of stem cell transplant
- UCB : No TBI (Type: EXPERIMENTAL): Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Umbilical Cord Blood (UCB) as a source of stem cell transplant
- UCB : No TBI/Bu/Cy/ATG (Type: EXPERIMENTAL): Patients who receives Umbilical Cord Blood (UCB) as a source of transplant and who have not had chemotherapy in the prior 3 months receives ATG in addition to cyclophosphamide, Busulfan preparative regimen
- PBSC (Type: EXPERIMENTAL): Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Peripheral blood stem cells as a source of transplant
- Marrow (Type: EXPERIMENTAL): Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Bone Marrow as a source of stem cell transplant
- UCB (Type: EXPERIMENTAL): Patients receiving cyclophosphamide, Total Body Irradiation (TBI), and Umbilical Cord Blood (UCB) as a source of stem cell transplant
- Co-Enroll From MT0403 (Type: EXPERIMENTAL): Patients receiving cyclophosphamide, Total Body Irradiation (TBI) , CD4+CD25+ and Peripheral Blood Stem Cells (PBSC) as a source of transplant. These patients are co-enrolled on the MT2004-03 trial (NCT00725062)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy